Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) Research & Development (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Research & Development data on record, last reported at $20.5 million in Q4 2021.

  • For Q4 2021, Research & Development rose 235.85% year-over-year to $20.5 million; the TTM value through Dec 2021 reached $55.9 million, up 117.24%, while the annual FY2025 figure was $269.8 million, 15.96% up from the prior year.
  • Research & Development reached $20.5 million in Q4 2021 per COGT's latest filing, up from $14.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $20.5 million in Q4 2021 and bottomed at $5.0 million in Q3 2020.
  • Average Research & Development over 4 years is $10.2 million, with a median of $10.3 million recorded in 2018.
  • Peak YoY movement for Research & Development: crashed 51.69% in 2020, then surged 235.85% in 2021.
  • A 4-year view of Research & Development shows it stood at $10.8 million in 2018, then decreased by 3.82% to $10.4 million in 2019, then tumbled by 41.01% to $6.1 million in 2020, then soared by 235.85% to $20.5 million in 2021.
  • Per Business Quant database, its latest 3 readings for Research & Development were $20.5 million in Q4 2021, $14.8 million in Q3 2021, and $12.4 million in Q2 2021.